Centex Studies-Lake Charles recently announced that the clinical investigational site in Lake Charles, Louisiana was selected by AstraZeneca for their Phase 2/3 clinical trial commencing in Mid-August. This clinical trial evaluates the safety and efficacy of AZD1222, one of the most promising of COVID-19 vaccines that was developed at University of Oxford, Jenner Institute. AstraZeneca reports that a single-dose of AZD1222 has triggered a four-fold increase in SARS-CoV-2 antibodies in 95% of those individuals vaccinated.
TrialSite can confidently report that AZD1222 represents one of the leading contenders among the investigational COVID-19 vaccines. As reported recently by KATC in Louisiana, the vaccine “uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.” With hope, the human immune system will be charged and ready to combat COVID-19, should it infect the body.
Who is Centex Studies?
Centex Studies is a site management organization with locations in Houston and McAllen Texas as well...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).